gsk201210116k2.htm
FORM 6-K
 
 
SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549
 
 
Report of Foreign Issuer
 
 
Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934
 
 
 
For period ending October 2012
 
GlaxoSmithKline plc
(Name of registrant)


 
 
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)


 
 
Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F


 
 
Form 20-F x     Form 40-F

 
--

 
Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.


 
 
Yes      No x
--




  
Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons
 
I give below details of the following increases in interests in American Depositary Shares (ADSs) of GlaxoSmithKline plc purchased at a price of $47.617 per ADS, in respect of the personal holdings of the under-mentioned persons
following the re-investment of the dividend paid to shareholders on 4
October
2012.
 
 
 
   Director/PDMR
 
 
 
   Number of ADSs
 
   Connected Person
 
   Number of ADSs
 
   Dr M M Slaoui
 
 
   670.314
 
   Dr K Slaoui
 
   11.992
 
   Mrs D P Connelly
 
   325.451
 
   -
 
   -
 
   Mr W C Louv
 
   283.937
 
   -
 
   -
 
   Dr D Pulman
 
 
   419.750
 
   -
 
   -
 
   Mr D E Troy
 
 
   167.801
 
 
   -
 
   -
 
 
The Company was advised of this information on 10 October 2012.
 
This notification relates to transactions notified in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
 
V A Whyte
Company Secretary
 
11 October 2012
 
 
 
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.



 
 
GlaxoSmithKline plc
(Registrant)


Date: October 11, 2012
 
 
By: VICTORIA WHYTE
------------------
 
 
Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc